Nathan D. Gay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nathan D. Gay has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Andy I. Chen
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
1 shared publicationCraig Y. Okada
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
1 shared publicationEmma C. Scott
Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA
1 shared publication
Latest Publications
- Open Access
- 28 March 2017
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 8 (5) , 175-180
Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab
Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous hematopoietic stem-cell transplantation and post-transplantation brentuximab vedotin. The purpose of this article is to review the immunophysiologic basis, clinical efficacy, and toxicity of nivolumab in the treatment of cHL. In addition, we will review ongoing clinical trials and potential future directions of checkpoint inhibition in the treatment of cHL.
- 28 March 2017
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 8 (5) , 175-180
Open AccessTargeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab
Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous hematopoietic stem-cell transplantation and post-transplantation brentuximab vedotin. The purpose of this article is to review the immunophysiologic basis, clinical efficacy, and toxicity of nivolumab in the treatment of cHL. In addition, we will review ongoing clinical trials and potential future directions of checkpoint inhibition in the treatment of cHL.